We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$6.85M
Cap. Flow
-$8.88M
Cap. Flow %
-0.86%
Top 10 Hldgs %
54.01%
Holding
84
New
13
Increased
14
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$21.3M
2
ANGO icon
AngioDynamics
ANGO
+$13.9M
3
XENT
Intersect ENT, Inc
XENT
+$11.1M
4
MDCO
Medicines Co
MDCO
+$9.01M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.81M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$18.7M
2
XNPT
XENOPORT, INC.
XNPT
+$7.18M
3
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$6.39M
4
ELOS
Syneron Medical Ltd
ELOS
+$6.36M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$5.34M

Sector Composition

Rank Sector Weight
1 Healthcare 73.33%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$786B
$115M 11.2%
+550,000
New +$114M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$113M 10.99%
6,863,848
+40,471
+0.6% +$655K
NVDQ
3
DELISTED
Novadaq Technologies Inc.
NVDQ
$53.8M 5.23%
5,465,216
– –
ANGO icon
4
AngioDynamics
ANGO
$564M
$51.8M 5.04%
3,607,282
+1,108,755
+44% +$13.9M
TVTX icon
5
Travere Therapeutics
TVTX
$5.18B
$47.4M 4.61%
2,662,591
-297,199
-10% -$4.81M
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$47.2M 4.59%
4,394,464
– –
PGNX
7
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$37.8M 3.67%
8,951,169
– –
RPTP
8
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$34.6M 3.37%
6,450,000
-550,000
-8% -$2.82M
NVRO
9
DELISTED
NEVRO CORP.
NVRO
$28.9M 2.81%
392,355
-275,552
-41% -$18.7M
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.26B
$25.7M 2.5%
3,170,759
+1,065,240
+51% +$6.69M
HRTX icon
11
Heron Therapeutics
HRTX
$90.5M
$22.6M 2.19%
1,250,104
-215,371
-15% -$4.2M
CSII
12
DELISTED
Cardiovascular Systems, Inc.
CSII
$22.6M 2.19%
1,227,501
-235,162
-16% -$3.67M
PETX
13
DELISTED
Aratana Therapeutics, Inc.
PETX
$21.7M 2.11%
3,428,865
– –
LJPC
14
DELISTED
La Jolla Pharmaceutical Company
LJPC
$20.5M 1.99%
1,281,373
+116,000
+10% +$2.08M
GNMX
15
DELISTED
Aevi Genomic Medicine Inc
GNMX
$18.7M 1.82%
3,370,306
+325,000
+11% +$1.71M
TLGT
16
DELISTED
Teligent, Inc
TLGT
$18M 1.75%
251,650
+22,877
+10% +$1.33M
SCTL
17
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$16.4M 1.59%
2,296,996
– –
ENDP
18
DELISTED
Endo International plc
ENDP
$16M 1.56%
+1,028,802
New +$21.3M
ATRS
19
DELISTED
Antares Pharma, Inc.
ATRS
$15.6M 1.52%
14,885,393
-200,000
-1% -$193K
ADXS
20
DELISTED
Advaxis Inc
ADXS
$13.7M 1.33%
112,701
– –
ARLZ
21
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$13.6M 1.32%
4,106,990
+306,990
+8% +$1.16M
ELGX
22
DELISTED
Endologix Inc
ELGX
$12.5M 1.21%
100,000
– –
BDSI
23
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$12.2M 1.19%
5,188,794
– –
RXDX
24
DELISTED
Ignyta, Inc.
RXDX
$12.2M 1.19%
2,256,546
– –
SPNE
25
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$11.5M 1.12%
1,100,007
+100,000
+10% +$1.21M
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Broadfin Capital held 84 positions worth $1.03B, down 0.66% from $1.04B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital's Q2 2016 filing shows 13 new, 14 increased, 14 reduced and 14 closed positions. Its largest new stake was Endo International plc: 1,028,802 shares worth $16M. The largest sale was NEVRO CORP., an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 71% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2016 buy was Endo International plc: 1,028,802 shares worth $16M.
  • Broadfin Capital added most to AngioDynamics in Q2 2016, an estimated $13.9M increase.
  • Broadfin Capital's biggest Q2 2016 reduction was NEVRO CORP., cutting an estimated $18.7M.
  • Broadfin Capital fully exited XENOPORT, INC. in Q2 2016, selling an estimated $7.18M.
  • Broadfin Capital's ten largest holdings make up 54% of its $1.03B portfolio in Q2 2016.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2016.
  • Broadfin Capital's portfolio value fell 0.66% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.